Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Phase 3 Completed NCT03872401

Summary

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First

From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months · Participants

Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First

From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
• Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
• Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke — Shionogi
• Zambia Stroke Unit Study — Johns Hopkins University
• Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

All trials